Principal Financial Group
SYRE icon

Principal Financial Group’s Spyre Therapeutics SYRE Stock Holding History

Principal Financial Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.3M Buy
59,747
+55,448
+1,290% +$4.05M ﹤0.01% 1655
2026
Q1 		$217K Buy
+4,299
New +$162K ﹤0.01% 2099
2021
Q1 		– Sell
-401
Closed -$79K – 2505
2020
Q4 		$79K Buy
+401
New +$83.1K ﹤0.01% 2374

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Principal Financial Group's SYRE Position: Q2 2026 in Review

Principal Financial Group increased its Spyre Therapeutics (SYRE) stake by 1,290% in Q2 2026, buying an estimated $4.05M and bringing the position to 59,747 shares worth $5.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Principal Financial Group first reported a position in SYRE in Q4 2020 and has held it in 3 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Principal Financial Group held 59,747 shares of Spyre Therapeutics worth $5.3M as of Q2 2026.
  • Principal Financial Group bought 55,448 Spyre Therapeutics shares in Q2 2026, an estimated $4.05M.
  • Spyre Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1655 holding.
  • Principal Financial Group first reported a position in Spyre Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.